Huahai Pharmaceuticals: Approval granted for candesartan hydrochlorothiazide tablets and hydrochloride rosuvastatin isopropanol ester injection.

Huahai Pharmaceutical announced that it has recently received the "Drug Registration Certificate" issued by the National Drug Administration for the approval of the production of candesartan cilexetil hydrochlorothiazide tablets and injection of rosoxacin hydrochloride acetate. Candesartan cilexetil hydrochlorothiazide tablets are used to treat hypertension, with an estimated domestic market sales of about 149 million yuan. Injection of rosoxacin hydrochloride acetate is used for low-risk patients with upper gastrointestinal bleeding, with an estimated domestic market sales of about 1.18 billion yuan. The company has invested about 11.28 million yuan in the development of candesartan cilexetil hydrochlorothiazide tablets and about 4.31 million yuan in the development of injection of rosoxacin hydrochloride acetate.